Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843310 · ClinicalTrials.gov registry record · Phase 2
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00843310: Clinical Trial Phase 2 study, sponsored by NYU Langone Health.
NCT00843310 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00843310, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side effects than similar combination induction treatment.
Primary Outcome
Toxicity will be scored using CTCAE version 3.0 for toxicity and adverse event reporting. Progressive Disease: requires any one or more of the following: 1. Increase of ≥25% from baseline in Serum M-component and/or (the absolute increase must be ≥0.5 g/dl)b 2. Urine M-component and/or (the absolute increase must be ≥200 mg/24 h 3. Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels. The absolute increase must be \>10
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Lenalidomide (Revlimid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Why NCT00843310 stopped before completion
NCT00843310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Melphalan is the first listed.
NCT00843310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00843310 about?
NCT00843310 is a clinical study titled "Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma". This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side effects than similar combination induction treatment.
What is the current status of trial NCT00843310?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00843310?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Lenalidomide (Revlimid) (DRUG).
Who is sponsoring clinical trial NCT00843310?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00843310's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia